Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.71 |
| ▸ | BLM | P54132 | 4/20 | 0.71 |
| ▸ | RECQL | P46063 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | APEX1 | P27695 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357420 | 1.00 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL6285299 | 1.00 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL1705642 | 1.00 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL13060220 | 0.86 | EGFR (0.77) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL5908882 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL29483469 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL29357482 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL6286665 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| SCHEMBL17457139 | 0.85 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 | |
| Tyrphostin 47 SCHEMBL5802735 | 0.83 | EGFR (1.00) | EGFRKDM4EMEN1KMT2AERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2020-10-29 | — | — | US | claimed |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2019-05-02 | — | — | US | claimed |
| EP-0614661-A2 | Benzylidene- and cinnamylidine-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-09-14 | — | — | EP | claimed |
| EP-0322738-A2 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-07-05 | — | — | EP | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4108248-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4477222-A2 | CRYSTALLINE 4-(5-CHLORO-2-ISOPROPYLAMINOPYRIDIN-4-YL)-1H-PYRROLE-2-CARBOXYLIC ACID [1-(3-CHLOROPHENYL)-2-HYDROXYETHYL]AMIDE HYDROCHLORIDE SALT | Biomed Valley Discoveries, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-3250562-B1 | CRYSTALLINE 4-(5-CHLORO-2-ISOPROPYLAMINOPYRIDIN-4-YL)-1H-PYRROLE-2-CARBOXYLIC ACID [1-(3-CHLOROPHENYL)-2-HYDROXYETHYL]AMIDE HYDROCHLORIDE SALT | BIOMED VALLEY DISCOVERIES INC (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | disclosed |
| US-20060167026-A1 | Antipsychotic molecular-targeting epithelial growth factor receptor | HIROYUKI NAWA (JP) | 2006-07-27 | — | — | US | disclosed |
| US-RE38761-E1 | Styryl compounds which inhibit EGF receptor protein tyrosine kinase | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-07-19 | — | — | US | disclosed |
| EP-0322738-B1 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RES DEV CO (IL) | 1995-04-12 | — | — | EP | disclosed |
| EP-0614661-A2 | Benzylidene- and cinnamylidine-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-09-14 | — | — | EP | disclosed |
| US-5217999-A | Antigrowth agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1993-06-08 | — | — | US | disclosed |
| WO-1991016892-A1 | STYRYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR PROTEIN TYROSINE KINASE | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| EP-0322738-A2 | Benzylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885KDM4E 4194/4885MEN1 63/4885 |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885KDM4E 4194/4885MEN1 63/4885 |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885KDM4E 4194/4885MEN1 63/4885 |
| US-20060167026-A1 | Antipsychotic molecular-targeting epithelial growth factor receptor | EGFR, BDNF, NTRK2 | EGFR 1/4885KDM4E 4214/4885MEN1 4424/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | EGFR 569/4885KDM4E 4194/4885MEN1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.